EUCTR2009-012269-71-FR进行中（未招募）1 期
Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 7,226
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Adults >18 years of age
- •- Type 2 diabetes mellitus
- •- Hospitalization for ACS event and randomization 2-6 weeks after day of hospitalization
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- eGFR <45 ml/in/1.73 m2
- •- Concomitant treatment with a thiazolidinedione and/or fibrate
- •- Triglycerides >400 mg/dL
- •- Symptomatic congestive heart failure classified as NYHA class II-IV
研究者
相似试验
进行中（未招募）
不适用
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes MellitusType 2 diabetes patients with a recent acute coronary syndrome (ACS) eventMedDRA version: 15.1Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersEUCTR2009-012269-71-SEF. Hoffmann-La Roche Ltd.7,000
进行中（未招募）
不适用
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes MellitusType 2 diabetes patients with a recent acute coronary syndrome (ACS) eventMedDRA version: 14.1Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersEUCTR2009-012269-71-CZF. Hoffmann-La Roche Ltd.7,000
进行中（未招募）
不适用
Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)Type 2 diabetes patients with a recent acute coronary syndrome (ACS) eventMedDRA version: 12.0Level: LLTClassification code 10007649Term: Cardiovascular disorderEUCTR2009-012269-71-HUF. Hoffmann-La Roche Ltd.6,000
进行中（未招募）
不适用
Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D). - ALECARDIOPatients with T2D and a recent ACS event.MedDRA version: 12.1Level: LLTClassification code 10007649Term: Cardiovascular disorderEUCTR2009-012269-71-ITF. Hoffmann-La Roche Ltd.6,000
已完成
3 期
A clinical trial to study reduction of cardiovascular mortality and morbidity in Type 2 diabetes mellitus patients with a recent Acutecoronarysyndrome eventCTRI/2010/091/000516The George Institute for international Health-India839C, Road No:44A, Jubilee Hills,Hyderabad-500033Andhra Pradesh- India6,000